At MPC Therapeutics, we are convinced that mitochondria, the small organelles at the core of the cell's metabolism, represent untapped therapeutic targets.
Headquartered in Switzerland, our startup is focused on cellular rejuvenation to improve the performance of cell therapies and treat degenerative pathologies.
Our novel approach uses proprietary first-in-class small molecules that specifically target mitochondria to trigger metabolic reprogramming.
Visit our website for more info.
Company Details
- Employees
- 7
- Founded
- 2018
- Address
- Chemin Des Aulx 14, Plan-Les-Ouates,geneva 1228,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.mpc-therapeutics.com
- HQ
- Plan-les-Ouates, Geneva
Mpc Therapeutics Questions
Mpc Therapeutics's website is http://www.mpc-therapeutics.com
Mpc Therapeutics's LinkedIn profile is https://ch.linkedin.com/company/mpc-therapeutics
Mpc Therapeutics has
7 employees.
View email and phone details for 7
employees at Mpc Therapeutics.
Mpc Therapeutics's industry is
Biotechnology Research
Mpc Therapeutics's top competitors are
Boltos,
Nxi Therapeutics Ag,
Fluosphera,
Gliapharm Sa,
Plutus Investment Group Llp,
Oxford Cancer Biomarkers,
Nuago Therapeutics,
Isospec Analytics,
Limula,
Cytea Bio.
Mpc Therapeutics's categories are Biotechnology Research
Mpc Therapeutics's founding year is 2018
